Drug Comparison
A side-by-side look at warfarin (a vitamin K antagonist) and Eliquis (apixaban, a Factor Xa inhibitor) — including available tablet strengths, monitoring requirements, diet interactions, reversal agents, and key clinical differences.
| Category | Warfarin | Eliquis (apixaban) |
|---|---|---|
| Drug class | Vitamin K antagonist | Direct Factor Xa inhibitor (DOAC) |
| Routine monitoring | Regular INR checks required | No routine monitoring |
| Predictability | Variable — affected by diet, genetics, other drugs | More predictable effect, consistent dosing |
| Diet interactions | Significantly affected by vitamin K-rich foods (leafy greens, etc.) | Not affected by dietary vitamin K |
| Drug interactions | Extensive — interacts with many antibiotics, OTC drugs, supplements | Fewer interactions (CYP3A4 / P-gp relevant) |
| Reversal agent | Vitamin K, PCC, or FFP | Andexanet alfa (AndexXa) |
| Mechanical heart valves | Approved — only option | Not approved |
| AFib / DVT / PE | Approved | Approved |
| Cost (typical) | Very low — generic, pennies per day | Higher — brand-name; cost varies with insurance |
| Onset of action | Slow — 2–5 days to full effect | Rapid — 3–4 hours to peak effect |
Warfarin is the only oral anticoagulant proven safe and effective for patients with mechanical prosthetic heart valves. Clinical trials of DOACs including apixaban in this setting were halted due to increased thromboembolic events and bleeding. If you have a mechanical valve, do not switch to Eliquis without specialist guidance.
Warfarin's therapeutic effect is measured by the INR (International Normalized Ratio). The target range varies by indication — typically 2.0–3.0 for AFib and DVT/PE, higher for some valve indications. Patients need regular blood draws, especially after any dose, diet, or medication change.
Eliquis (apixaban) provides consistent anticoagulation without routine monitoring, which many patients find more convenient. Its effect cannot be easily measured with standard tests like PT/INR, which can complicate management in emergencies or before surgery.
Both drugs require caution in kidney disease. Warfarin is sometimes preferred when renal function is severely impaired, as more of Eliquis is renally cleared. Eliquis has a renal dose reduction criteria: 2.5 mg twice daily if two of three criteria apply (age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL).
Both warfarin and Eliquis carry risks in pregnancy. Warfarin crosses the placenta and can cause fetal harm. Eliquis is generally not recommended during pregnancy due to lack of safety data. Discuss anticoagulation options with your OB and hematologist or cardiologist if pregnant or planning a pregnancy.
Warfarin has been in clinical use since the 1950s, giving it one of the most extensive real-world safety profiles of any medication. Eliquis received FDA approval in 2012 and has since become widely used, with a strong evidence base — but the decades-long warfarin record remains unmatched.